Polar Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Polar Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-50,000	Closed	-$6.26M	–	295
2019 Q1	$6.26M	Sell	50,000 -25,000	-33%	-$3.11M	0.06%	208
2018 Q4	$8.45M	Buy	+75,000	New	+$11.6M	0.09%	182
2018 Q2	–	Sell	-200,000	Closed	-$23.4M	–	264
2018 Q1	$23.4M	Buy	200,000 +20,000	+11%	+$2.47M	0.24%	132
2017 Q4	$16.5M	Buy	+180,000	New	+$10.3M	0.17%	143

Other funds holding MDGL

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Polar Capital's MDGL Position: Q2 2019 in Review

Polar Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2019, closing a stake of 50,000 shares — an estimated $6.26M sold.

Polar Capital first reported a position in MDGL in Q4 2017 and held it in 4 quarters. The position peaked at $23.4M in Q1 2018. 116 funds tracked by Wall St. Rank hold MDGL as of Q2 2019.

Polar Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Polar Capital sold 50,000 Madrigal Pharmaceuticals shares in Q2 2019, an estimated $6.26M.
Polar Capital first reported a position in Madrigal Pharmaceuticals in Q4 2017 and held it in 4 quarters.
Polar Capital's Madrigal Pharmaceuticals position peaked at $23.4M in Q1 2018.
116 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2019.

Based on Polar Capital's 13F filing for Q2 2019, filed 14 Aug 2019.